Arcutis Biotherapeutics Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Arcutis Biotherapeutics is forecast to grow earnings and revenue by 69.1% and 34.6% per annum respectively. EPS is expected to grow by 69.3% per annum. Return on equity is forecast to be -45.2% in 3 years.
Anahtar bilgiler
69.1%
Kazanç büyüme oranı
69.3%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | 34.6% |
| Gelecekteki özkaynak getirisi | -45.2% |
| Analist kapsamı | Good |
| Son güncelleme | 22 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 395 | -2 | 40 | -45 | 7 |
| 12/31/2025 | 249 | -135 | -77 | -121 | 7 |
| 12/31/2024 | 162 | -184 | -160 | -180 | 7 |
| 6/30/2024 | 132 | -199 | -177 | -177 | N/A |
| 3/31/2024 | 106 | -217 | -199 | -198 | N/A |
| 12/31/2023 | 60 | -262 | -247 | -247 | N/A |
| 9/30/2023 | 49 | -268 | -262 | -262 | N/A |
| 6/30/2023 | 12 | -331 | -309 | -286 | N/A |
| 3/31/2023 | 6 | -327 | -304 | -281 | N/A |
| 12/31/2022 | 4 | -311 | -281 | -258 | N/A |
| 9/30/2022 | 1 | -311 | -262 | -238 | N/A |
| 6/30/2022 | N/A | -260 | -212 | -212 | N/A |
| 3/31/2022 | N/A | -235 | -186 | -185 | N/A |
| 12/31/2021 | N/A | -206 | -176 | -175 | N/A |
| 9/30/2021 | N/A | -169 | -156 | -155 | N/A |
| 6/30/2021 | N/A | -150 | -149 | -148 | N/A |
| 3/31/2021 | N/A | -144 | -139 | -138 | N/A |
| 12/31/2020 | N/A | -136 | -113 | -113 | N/A |
| 9/30/2020 | N/A | -114 | -97 | -97 | N/A |
| 6/30/2020 | N/A | -90 | -74 | -74 | N/A |
| 3/31/2020 | N/A | -63 | -57 | -57 | N/A |
| 12/31/2019 | N/A | -42 | -43 | -43 | N/A |
| 9/30/2019 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2019 | N/A | -28 | -24 | -24 | N/A |
| 3/31/2019 | N/A | -23 | -19 | -18 | N/A |
| 12/31/2018 | N/A | -19 | -14 | -14 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARQT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Kazançlar ve Piyasa: ARQT is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: ARQT is expected to become profitable in the next 3 years.
Gelir ve Pazar: ARQT's revenue (34.6% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: ARQT's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARQT is forecast to be unprofitable in 3 years.